Methods for selecting microbes from a diverse genetically modified library to detect and optimize the production of metabolites

Patent metadata

Field	Value
Publication number	US-10550384-B2
Application number	US-201414775025-A
Country	US
Kind code	B2
Filing date	Feb 26, 2014
Priority date	Mar 14, 2013
Publication date	Feb 4, 2020
Grant date	Feb 4, 2020

Abstract

The present invention relates to genetically modified bacteria and methods of optimizing genetically modified bacteria for the production of a metabolite.

First claim

What is claimed is:

1. A method of selecting a subset of microbes for the production of a metabolite comprising
placing a population of microbes in an environment of a toxin, wherein the toxin is external to the population of microbes,
wherein the population of microbes has been genetically modified to include exogenous DNA encoding for an antidote gene to the toxin,
wherein the population of microbes has been genetically modified to include exogenous DNA encoding a sensor biomolecule which when expressed regulates expression of the antidote gene by the microbes through a cognate nucleic acid sequence located 5′ to the DNA encoding the antidote gene, wherein the sensor biomolecule is a transcription factor, riboswitch, two-component signaling protein or a nuclear hormone receptor,
wherein the population of microbes has been genetically modified to include exogenous DNA encoding genes to produce a metabolite binding partner of the sensor, which when produced binds to the sensor to induce expression of the antidote gene in a manner dependent on the concentration of the produced metabolite, and
selecting a subset of microbes that produce sufficient metabolite to prevent microbe death,
wherein the sensor biomolecule and its corresponding metabolite binding partner is selected from the group consisting of cdaR and glucaric acid, ttgR and naringennin, btuB riboswitch and cobalamin, mphR and macrolides, benM and muconic acid, alkS and medium chain n-alkanes, xylR and xylose, araC and arabinose, gntR and Gluconate, galS and galactose, trpR and tryptophan, qacR and berberine, rmrR and Phytoalexin, cymR and cumate, melR and melibiose, rafR and raffinose, nahR and salicylate, nocR and nopaline, clcR and Chlorobenzoate, varR and virginiamycin, rhaR and rhamnose, PhoR and phosphate, MalK and malate, GlnK and glutamine, retinoic acid receptor and retinoic acid, estrogen receptor and estrogen, and ecdysone receptor and ecdysone,
wherein the toxin and antidote pair is selected from the group consisting of SDS:tolC, colicin:tolC (negative selection), kanamycin:kanamycin nucleotidyltransferase, chloramphenicol:chloramphenicol acyl transferase, ampicillin:beta lactamase, tetracycline:tetracycline efflux pump tetA, nickel chloride:tetracycline efflux pump tetA (negative selection), and 5-fluoroorotic acid:URA3 (negative selection).

2. The method of claim 1 further comprising
genetically modifying the subset of microbes to alter genes that affect production of the metabolite directly or indirectly,
subjecting the subset of microbes to a subsequent environment of the toxin having a concentration greater than the previous environment,
and selecting a subsequent subset of microbes the produce sufficient metabolite to prevent microbe death.

3. The method of claim 2 further comprising
repeating in sequence: (1) genetically modifying the subsequent subset of microbes by altering genes that affect the production of the metabolite, (2) subjecting the genetically altered microbes to a subsequent environment of a toxin having a concentration greater than a previous environment, and (3) selecting a further subsequent subset of microbes that produce sufficient metabolite to prevent microbe death, said repeating step resulting in optimized metabolite producing microbes.

4. The method of claim 1 wherein binding of the metabolite to the sensor regulates gene expression to induce production of the antidote gene in a manner dependent on the concentration of the expressed metabolite.

5. The method of claim 4 wherein a positive selection marker is used to select the subset of microbes that produce sufficient metabolite to prevent microbe death.

6. The method of claim 4 wherein the sensor regulates the expression of two or more antidote genes independently and two or more toxins are used to select the subset of microbes that produce sufficient metabolite to prevent microbe death.

7. The method of claim 1 wherein binding of the metabolite to the sensor regulates gene expression to induce production of the antidote gene in a manner dependent on the concentration of the expressed metabolite.

8. The method of claim 7 wherein a negative selection marker is used to eliminate false positives that detoxify the microbe despite not producing sufficient metabolite.

9. The method of claim 1 wherein the population of microbes have been genetically modified to include two or more redundant copies of the exogenous DNA encoding the sensor in order to reduce false positives.

10. The method of claim 1 wherein the sensor also regulates its own expression through a cognate nucleic acid sequence located 5′ to the DNA sequence encoding the sensor in order to reduce false positives.

11. The method of claim 1 wherein the degradation rate of the antidote gene is increased by encoding a degradation signal within the antidote gene in order to reduce false positives.

12. The method of claim 2 wherein the step of genetically modifying the subset of microbes to alter genes that produce the metabolite includes multiplexed automated genome engineering.

13. The method of claim 2 wherein the step of genetically modifying the subset of microbes includes making a plasmid library of pathway genes.

14. The method of claim 2 wherein the step of genetically modifying the subset of microbes includes making a plasmid library of genomic fragments of any organism.

15. The method of claim 2 wherein the step of genetically modifying the subset of microbes includes making a plasmid library of metagenomic sequences.

16. The method of claim 12 wherein the multiplexed automated genome engineering includes reducing spontaneous background mutants.

17. The method of claim 12 wherein the multiplexed automated genome engineering includes reducing spontaneous background mutants by pretreatment with a negative selector.

18. The method of claim 1 wherein concentration of the metabolite exposed to the sensor is attenuated.

19. The method of claim 18 wherein the concentration of the metabolite exposed to the sensor is attenuated by expressing one or more proteins to export the metabolite outside of the cell.

20. The method of claim 18 wherein the concentration of the metabolite exposed to the sensor is attenuated by expressing one or more enzymes that convert the metabolite to another metabolite having less interaction with the sensor.

21. The method of claim 18 wherein the concentration of the metabolite exposed to the sensor is attenuated by expressing a biomolecule that binds to the metabolite and reduces its interaction with the sensor.

Assignees

• Harvard College

Inventors

• Church George M
• Raman Srivatsan
• Taylor Noah D
• Rogers Jameson

Classifications

• C12P29/00

  Preparation of compounds containing a naphthacene ring system, e.g. tetracycline (C12P19/00 takes precedence) · CPC title

• C12N1/38

  Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound (C12N1/34 takes precedence) · CPC title

• C12P19/42

  Cobalamins, i.e. vitamin B12, LLD factor · CPC title

• C12P7/58

  Aldonic, ketoaldonic or saccharic acids (uronic acids C12P19/00) · CPC title

• C12N15/63

  Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title